Characteristics and response rate of first and subsequent salvage treatments
| Treatment group . | First line of salvage treatment . | All lines of salvage treatment . | ||||||
|---|---|---|---|---|---|---|---|---|
| N . | % used . | N ≥ PR ORR . | N ≥ VGPR % . | N . | % used . | N ≥ PR ORR . | N ≥ VGPR % . | |
| Allo-SCT | 0 | 0.0% | 0/0 N/A | 0/0 N/A | 7 | 3.0% | 4/4 100.0% | 2/4 50.0% |
| Auto-SCT | 3 | 3.8% | 1/3 33.3% | 1/3 33.3% | 14 | 5.9% | 10/14 71.4% | 7/14< 50.0% |
| BCMA ADC | 1 | 1.3% | 0/1 0.0% | 0/1 0.0% | 9 | 3.8% | 2/8 25.0% | 2/8 25.0% |
| Bispecific trial | 11 | 13.9% | 7/10 70.0% | 5/10 50.0% | 32 | 13.5% | 17/29 58.6% | 12/29 41.4% |
| BCMA-directed bispecific trial | 2 | 2.5% | 1 out of 2 50.0% | 0 out of 2 0.0% | 9 | 3.8% | 4 out of 9 44.4% | 3 out of 9 33.3% |
| Non-BCMA–directed bispecific trial | 9 | 11.4% | 6 out of 8 75.0% | 5 out of 8 62.5% | 23 | 9.7% | 13 out of 20 65.0% | 9 out of 20 45.0% |
| CAR T trial | 2 | 2.5% | 2 out of 2 100.0% | 1 out of 2 50.0% | 6 | 2.5% | 5 out of 6 83.3% | 3 out of 6 50.0% |
| Chemotherapy with or without stem cell support | 20 | 25.3% | 11 out of 19 57.9% | 4 out of 19 21.1% | 53 | 22.4% | 29 out of 51 56.9% | 12 out of 51 23.5% |
| Doublet/triplet/quadruplet combination of approved agents | 23 | 29.1% | 7 out of 22 31.8% | 2 out of 22 9.1% | 56 | 23.6% | 15 out of 53 28.3% | 4 out of 53 7.5% |
| Selinexor-based therapy | 5 | 6.3% | 2 out of 5 40.0% | 2 out of 5 40.0% | 15 | 6.3% | 3 out of 14 21.4% | 3 out of 14 21.4% |
| Venetoclax-based therapy | 3 | 3.8% | 2 out of 3 66.7% | 1 out of 3 33.3% | 14 | 5.9% | 5 out of 14 35.7% | 2 out of 14 14.3% |
| Other combinations (including MAPKi, checkpoint inhibitor or other trial) | 11 | 13.9% | 1 out of 11 9.1% | 0 out of 11 0.0% | 31 | 13.1% | 12 out of 31 38.7% | 1 out of 31 3.2% |
| All treatment groups | 79 | 100.0% | 33 out of 76 43.4% | 16 out of 76 21.1% | 237 | 100.0% | 101 out of 224 45.1% | 48 out of 224 21.4% |
| Total N = 79 | Total N = 76 | Total N = 237 | Total N = 224 | |||||
| Treatment group . | First line of salvage treatment . | All lines of salvage treatment . | ||||||
|---|---|---|---|---|---|---|---|---|
| N . | % used . | N ≥ PR ORR . | N ≥ VGPR % . | N . | % used . | N ≥ PR ORR . | N ≥ VGPR % . | |
| Allo-SCT | 0 | 0.0% | 0/0 N/A | 0/0 N/A | 7 | 3.0% | 4/4 100.0% | 2/4 50.0% |
| Auto-SCT | 3 | 3.8% | 1/3 33.3% | 1/3 33.3% | 14 | 5.9% | 10/14 71.4% | 7/14< 50.0% |
| BCMA ADC | 1 | 1.3% | 0/1 0.0% | 0/1 0.0% | 9 | 3.8% | 2/8 25.0% | 2/8 25.0% |
| Bispecific trial | 11 | 13.9% | 7/10 70.0% | 5/10 50.0% | 32 | 13.5% | 17/29 58.6% | 12/29 41.4% |
| BCMA-directed bispecific trial | 2 | 2.5% | 1 out of 2 50.0% | 0 out of 2 0.0% | 9 | 3.8% | 4 out of 9 44.4% | 3 out of 9 33.3% |
| Non-BCMA–directed bispecific trial | 9 | 11.4% | 6 out of 8 75.0% | 5 out of 8 62.5% | 23 | 9.7% | 13 out of 20 65.0% | 9 out of 20 45.0% |
| CAR T trial | 2 | 2.5% | 2 out of 2 100.0% | 1 out of 2 50.0% | 6 | 2.5% | 5 out of 6 83.3% | 3 out of 6 50.0% |
| Chemotherapy with or without stem cell support | 20 | 25.3% | 11 out of 19 57.9% | 4 out of 19 21.1% | 53 | 22.4% | 29 out of 51 56.9% | 12 out of 51 23.5% |
| Doublet/triplet/quadruplet combination of approved agents | 23 | 29.1% | 7 out of 22 31.8% | 2 out of 22 9.1% | 56 | 23.6% | 15 out of 53 28.3% | 4 out of 53 7.5% |
| Selinexor-based therapy | 5 | 6.3% | 2 out of 5 40.0% | 2 out of 5 40.0% | 15 | 6.3% | 3 out of 14 21.4% | 3 out of 14 21.4% |
| Venetoclax-based therapy | 3 | 3.8% | 2 out of 3 66.7% | 1 out of 3 33.3% | 14 | 5.9% | 5 out of 14 35.7% | 2 out of 14 14.3% |
| Other combinations (including MAPKi, checkpoint inhibitor or other trial) | 11 | 13.9% | 1 out of 11 9.1% | 0 out of 11 0.0% | 31 | 13.1% | 12 out of 31 38.7% | 1 out of 31 3.2% |
| All treatment groups | 79 | 100.0% | 33 out of 76 43.4% | 16 out of 76 21.1% | 237 | 100.0% | 101 out of 224 45.1% | 48 out of 224 21.4% |
| Total N = 79 | Total N = 76 | Total N = 237 | Total N = 224 | |||||
PR, partial response; VGPR, very good partial response.